<DOC>
<DOCNO>EP-0637631</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Highly efficient expression of a polypeptide containing a modified preS1 region of the major hepatitis B virus antigen.
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3900	A61K3900	C07K14005	C07K1402	C12N701	C12N701	C12N1551	C12N1551	C12P2108	C12P2108	G01N33576	G01N33576	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	C07K	C07K	C12N	C12N	C12N	C12N	C12P	C12P	G01N	G01N	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K39	A61K39	C07K14	C07K14	C12N7	C12N7	C12N15	C12N15	C12P21	C12P21	G01N33	G01N33	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The present invention relates to processes for preparing recombinant molecules which comprise the nucleotide sequence for the structure of the preS1 region of the surface glycoprotein of hepatitis B virus, and to compositions of these molecules. The compositions of the recombinant molecules can comprise a promoter and a marker gene. Cloning vectors are used to integrate the recombinant molecules into host vectors (vaccinia virus). Cells infected with the chimeric vaccinia viruses produce large amounts of preS1 protein. Isolation and purification of the preS1-containing protein are facilitated by using a recombinant molecule in which the myristylation site has been deleted by modification of the nucleotide sequence. The purified preS1-containing protein is suitable for developing vaccines, diagnostic reagent kits and therapies.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
IMMUNO AG
</APPLICANT-NAME>
<APPLICANT-NAME>
IMMUNO AKTIENGESELLSCHAFT
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
DORNER FRIEDRICH PROF
</INVENTOR-NAME>
<INVENTOR-NAME>
FALKNER FALKO-GUENTER
</INVENTOR-NAME>
<INVENTOR-NAME>
PFLEIDERER MICHAEL DR
</INVENTOR-NAME>
<INVENTOR-NAME>
DORNER, FRIEDRICH, PROF.
</INVENTOR-NAME>
<INVENTOR-NAME>
FALKNER, FALKO-GUENTER
</INVENTOR-NAME>
<INVENTOR-NAME>
PFLEIDERER, MICHAEL, DR.
</INVENTOR-NAME>
</INVENTORS>
</TEXT>
</DOC>
